Skip links


The Ventures Co., Ltd. Invests in AI DNA Information Solution ‘Genealogy Inc.’

Genetic testing high resolution DNA information prediction… Blood cancer treatment, organ transplant matching test is expected to decrease

[Medicine Newspaper / Daily Newspaper = Reporter In-Kyu Oh] TheVentures Co., Ltd. (CEO Ho Chang-Sung) invests seed in bioinformatics startup Genealogy Inc. (Andrew Chi, CEO), which extracts high-resolution DNA data from simple DNA test (SNP test) data. It was announced on the 6th that it was executed.

To solve the problem that the existing HLA(human leukocyte antigen) genotyping is expensive and takes a long time, the algorithm uses the original data of the simple genetic test(SNP test) to predict the HLA gene and genotype.

At the same time, the company plans to build a platform for uploading and converting general-purpose genetic test data, and to present AI-based DNA information prediction systems for confirming immunogenotype conformity.

The United States is a large-growth market that predicts that by the year 2021, 100 million of adults will use the DTC gene test cumulatively, taking advantage of the ease of building a DNA information database in the country. The allergy will enter the US market first.

In particular, the HLA genotyping test is necessary before blood transfusion treatment and organ transplant surgery for the treatment of blood cancer, and is also essential for the treatment of autoimmune diseases such as atopy, diabetes, and rheumatoid arthritis. Demand is expected to increase exponentially according to the related research results.

“We deeply sympathized with the vision of Genealogy Inc., a company that saves lives through technology and equipped with experts in the biotechnology field and experts in the global IT business field, who can make this happen. I highly appreciated the team. ”

Professor Han Bum of Seoul National University, who is in charge of technology development, said, “By predicting bioinformation faster and more accurately based on DNA, the diseases that can be overcome will increase.” ‘We plan to develop a HLA matching service for blood cancer patients that can determine whether patients and their families match, and increase related services step by step.’

Original Article:

AI-Based DNA Information Amplification Solution ‘Genealogy Inc.’ Selected by TIPS Program

On the 3rd, Genealogy Inc. (CEO Andrew Chi) announced that it was finally selected for the TIPS program, a private investment-led technology start-up support program.

Genealogy Inc. is a bioinformatics startup that extracts high-resolution DNA data from simple DNA test (SNP test) data. We are developing an algorithm that predicts the genotype and genotype of HLA using the original data of the simple genetic test (SNP test). Through this, it is solving the problem of the existing HLA (histocompatibility antigen) genotyping, which is expensive and time-consuming. The HLA genotyping test is essential before blood transfusion and organ transplant surgery and is also essential for the treatment of autoimmune diseases such as diabetes and atopy. In the United States alone, there is a need for over 2 million direct tests per year.

Recently, Covid-19 infection has become prevalent, interest in human immunity is increasing, and demand for related technologies is rapidly increasing. As Genealogy Inc’s DNA information amplification solution targets the HLA genotype, the gene that has the greatest influence on human immunity, we are also looking for ways to utilize it in the future.

“We are a team of experts in the bioinformatics field and experts in the global IT business field, and it is very positive that real technology is very likely to be implemented. It seems to be evaluated. ”

“We are developing ‘HLA matching service for hematologic cancer patients,’ which can find out whether patients and their families are matched online, without expensive DNA testing,” said Han Beom, associate professor of Seoul National University Medical School, who is in charge of Genealogy Inc., “With this TIPS program, the development of related services such as a platform for general purpose genetic testing data and an AI-based DNA information prediction system for confirming immunogenotype matching will be accelerated.”

Original Article:

Leave a comment